Abstract
The pyrrolo[2,3-d]pyrimidine nucleus is a deaza-isostere of adenine, the nitrogenous base of ATP, and is present in many ATP-competitive inhibitors of different kinases. In the last few years the number of articles and patents that have appeared involving this type of inhibitors has dramatically increased and some compounds have been approved for the treatment of inflammatory or myeloproliferative diseases. Other derivatives are currently being evaluated in clinical trials. This review deals with pyrrolo[2,3- d]pyrimidine derivatives active as kinase inhibitors that have been reported in the literature from 2011 to 2016, with a particular interest on the recently patented compounds. The molecules are classified depending on the inhibited kinase, focusing on their chemical structures.
Keywords: Pyrrolo[2, 3-d]pyrimidine, kinase inhibitors, patents, anticancer agents, anti-inflammatory agents.
Current Medicinal Chemistry
Title:Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Volume: 24 Issue: 19
Author(s): Francesca Musumeci, Monica Sanna, Giancarlo Grossi, Chiara Brullo, Anna Lucia Fallacara and Silvia Schenone*
Affiliation:
- Dipartimento di Scienze Farmaceutiche, Università degli Studi di Genova, Viale Benedetto XV, 3, I-16132, Genova,Italy
Keywords: Pyrrolo[2, 3-d]pyrimidine, kinase inhibitors, patents, anticancer agents, anti-inflammatory agents.
Abstract: The pyrrolo[2,3-d]pyrimidine nucleus is a deaza-isostere of adenine, the nitrogenous base of ATP, and is present in many ATP-competitive inhibitors of different kinases. In the last few years the number of articles and patents that have appeared involving this type of inhibitors has dramatically increased and some compounds have been approved for the treatment of inflammatory or myeloproliferative diseases. Other derivatives are currently being evaluated in clinical trials. This review deals with pyrrolo[2,3- d]pyrimidine derivatives active as kinase inhibitors that have been reported in the literature from 2011 to 2016, with a particular interest on the recently patented compounds. The molecules are classified depending on the inhibited kinase, focusing on their chemical structures.
Export Options
About this article
Cite this article as:
Musumeci Francesca , Sanna Monica , Grossi Giancarlo , Brullo Chiara, Fallacara Lucia Anna and Schenone Silvia *, Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors, Current Medicinal Chemistry 2017; 24 (19) . https://dx.doi.org/10.2174/0929867324666170303162100
DOI https://dx.doi.org/10.2174/0929867324666170303162100 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents on Imaging Nanoprobes for Brain Tumor Diagnosis and Therapy
Recent Patents on Biotechnology Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets Decreased Serum Adiponectin Level Affected Clinical Pathological Characteristics of Patients with Gastric Cancer
Current Proteomics Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Cannabinoid Receptors as Therapeutic Targets
Current Pharmaceutical Design Anti-cancer Effect of Cyanidin-3-glucoside from Mulberry via Caspase-3 Cleavage and DNA Fragmentation in vitro and in vivo
Anti-Cancer Agents in Medicinal Chemistry Cells with Minimal Expression of the JAK/STAT Pathway Related Proteins STAT5a and the Prolactin Receptor: Evidence of an Alternate Prolactin Receptor Isoform in Breast Disease
Protein & Peptide Letters Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design Efficacy of PD-1 or PD-L1 Inhibitors and Central Nervous System Metastases in Advanced Cancer: A Meta-Analysis
Current Cancer Drug Targets New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry The cytotoxic effect of GW843682X on nasopharyngeal carcinoma
Anti-Cancer Agents in Medicinal Chemistry siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors
Drug Metabolism Letters Small Molecular Leads Differentially Active Against HER2 Positive and Triple Negative Breast Cancer Cell Lines
Medicinal Chemistry Comparing High LET <sup>227</sup>Th- and Low LET <sup>177</sup>Lu-trastuzumab in Mice with HER-2 Positive SKBR-3 Xenografts
Current Radiopharmaceuticals Nanomaterials for Photohyperthermia: A Review
Current Pharmaceutical Design Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Vascular Endothelial Growth Factor (VEGF) Inhibition - A Critical Review
Anti-Cancer Agents in Medicinal Chemistry Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Current Topics in Medicinal Chemistry